SABS's Quality Score rose 1 point on Mon, Oct 26, to -4. Its volume went quiet.
Follow SABS's trial news. Pro members can get an alert when SAB Biotherapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 71% over three years while the S&P 500 rose 87%.
“Revenue decreased by $1.3 million, or 100.0%, in 2025, primarily due to the JPEO Rapid Response Contract Termination.”
3 more reasons why SABS lags the market, from its filings, with the company's words and the timeline, for Pro members.
| Since its Dec 2021 high | Down 97% |
| Latest filing | 8-K, Oct 13 |
5 more reasons behind SABS's -4, for Pro members.
After its last 2 reports it closed -0.3% on average, higher 1 of 2 times.
About 7 quarters
No shelf registration or at-the-market program on file in the last three years.
No open-market buys or sales by its officers or directors in their filings of the last year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
PoorTrending down, 1 of 14 chart checks firingWhat the Quality Score means
SABS is #210 of 291 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 210 |
Expected to report Thu Nov 12, before the open (in 17 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 6, 2026 | -0.3% | +2.1% | +0.8% |
| May 12, 2026 | +2.1% | -2.7% | -4.3% |
Officers and directors with a Form 4 in the last 12 months.
In ETFs: SABS is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
“The biopharmaceutical industry is highly competitive and subject to rapid and significant technological change as research provides a deeper understanding of the pathology of diseases and new technologies and treatments are developed.”
SABS scores -4 today, which Breakaway calls Poor. It is #210 of 291 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 71% over three years while the S&P 500 rose 87%. Cash lasts about 7 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
SABS scores -4 today, which Breakaway calls Poor (below zero). That is #210 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind SABS's -4.
Expected to report Thu Nov 12, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. SABS closed higher after 1 of its last 2 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.